A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4275-4279

  Zustovich, Fable ^a   Lombardi, Giuseppe ^a   Della Puppa, Alessandro ^b   Rotilio, Antonino ^b   Scienza, Renato ^b   Pastorelli, Davide ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemotherapy; Cisplatin; Gliomas; Malignant; Temozolomide

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; CISPLATIN; DEXAMETHASONE SODIUM PHOSPHATE; FOTEMUSTINE; GRANISETRON; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EPIGASTRIC PAIN; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; MALE; MISMATCH REPAIR; MYALGIA; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 71949130289     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Westphal M, Ram Z, Riddle V, Hilt D and Bortey E: Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148: 269-275, 2006. (Pubitemid 43341024)
2. Stupp R, Mason WP, van den Bent MJ, Weiler M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
3. Rich J, Affronti M, Day J, Herndon J, Quinn J, Reardon D, Vredenburgh J, Desjardins A and Friedman H: Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. Proc Am Soc Clin Oncol 25: 2070, 2007.
4. Goli K, Desjardins A, Herndon JE, Rich JN, Reardon DA, Quinn JA, Sathornsumetee S, Bota DA, Friedman HS and Vredenburgh J: Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. Proc Am Soc Clin Oncol 25: 2003, 2007.
5. 6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 15: 279-292, 1988. (Pubitemid 19105392)
6. D'Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E and Margison GP: Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294: 664-671, 2000. (Pubitemid 30490843)
7. Macdonald DR, Cascino TL, Schold SC Jr and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
8. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S and Ermani M: First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 22: 1598-1604, 2004. (Pubitemid 41079797)
9. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F and Ermani M: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197, 2008.
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)